- GlobeNewswire•24 days agoChemoCentryx Reports Initial Results from Ongoing Phase Ib Clinical Trial of CCX872 in Patients with Advanced Pancreatic Cancer
MOUNTAIN VIEW, Calif., Sept. 01, 2016-- ChemoCentryx, Inc., today announced initial 12 week overall response rate results from an ongoing open label, single arm Phase Ib clinical trial with CCX872 in patients ...
- GlobeNewswire•last month
MOUNTAIN VIEW, Calif., Aug. 25, 2016-- ChemoCentryx, Inc.,, a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, ...
ChemoCentryx, Inc. (CCXI)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||4.24 x 600|
|Ask||5.32 x 100|
|Day's Range||5.14 - 5.28|
|52wk Range||1.92 - 8.30|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.79|
|Avg Vol (3m)||188,752|
|Dividend & Yield||N/A (N/A)|